Target expression details
| Target General Information | |||||
|---|---|---|---|---|---|
| Target ID | T61698 | ||||
| Target Name | Interleukin-2 | ||||
| Synonyms | Aldesleukin; IL-2; T-cell growth factor; TCGF; IL2 | ||||
| Target Type | Successful | ||||
| Gene Name | IL2 | ||||
| Biochemical Class | Cytokine: interleukin | ||||
| UniProt ID | IL2_HUMAN | ||||
| Target Gene Expression Profiles in the Disease-Relevant Drug Targeted Tissue of the Patients and Healthy Individuals | |||||
| Disease | Bipolar disorder | ||||
| Example drug | TG-4010 | Phase 2/3 | [1], [2] | ||
| Tissue | Pre-frontal cortex | ||||
| Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual | Fold-change: 1.04E-02 Z-score: 0.07 P-value: 7.64E-01 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
|
|||||
| Disease | Melanoma | ||||
| Example drug | APN-301 | Phase 2 | [3], [2] | ||
| Tissue | Skin | ||||
| Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual | Fold-change: -0.07 Z-score: -0.16 P-value: 4.26E-01 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
|
|||||
| Disease | Renal cancer | ||||
| Example drug | Human interleukin-2 | Phase 2 | [4], [2] | ||
| Tissue | Kidney | ||||
| Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual | Fold-change: 0.13 Z-score: 0.59 P-value: 5.88E-01 |
||||
| Level of differential expression between the patients in the disease section of the tissue and the patients in the normal section of the tissue adjacent to the disease section | Fold-change: -0.03 Z-score: -0.15 P-value: 7.32E-01 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of healthy individual
|
|||||
| Disease | Ovarian cancer | ||||
| Example drug | IL-2/gene-modified lymphocytes | Phase 1/2 | [5], [2] | ||
| Tissue | Ovarian tissue | ||||
| Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual | Fold-change: -0.05 Z-score: -0.47 P-value: 9.48E-01 |
||||
| Level of differential expression between the patients in the disease section of the tissue and the patients in the normal section of the tissue adjacent to the disease section | Fold-change: 0.03 Z-score: 0.13 P-value: 6.57E-01 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of healthy individual
|
|||||
| Disease | Prostate cancer | ||||
| Example drug | VPM-4-001 | Preclinical | [6], [2] | ||
| Tissue | Prostate | ||||
| Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual | Fold-change: 0.40 Z-score: 1.20 P-value: 7.29E-07 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
|
|||||
| Disease | Lung cancer | ||||
| Example drug | VLTS-587 | Discontinued in Phase 2 | [7], [2] | ||
| Tissue | Lung tissue | ||||
| Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual | Fold-change: 2.69E-03 Z-score: 0.02 P-value: 3.67E-01 |
||||
| Level of differential expression between the patients in the disease section of the tissue and the patients in the normal section of the tissue adjacent to the disease section | Fold-change: 0.03 Z-score: 0.20 P-value: 1.33E-02 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of healthy individual
|
|||||
| Disease | Rheumatoid arthritis | ||||
| Example drug | Roquinimex | Discontinued in Phase 1 | [8], [2] | ||
| Tissue | Synovial tissue | ||||
| Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual | Fold-change: -0.13 Z-score: -0.88 P-value: 4.71E-01 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
|
|||||
| Target Gene Expression Profiles in Other Tissues of Healthy Individuals | |||||
|
|||||
| Reference | |||||
| REF 1 | A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer. J Thorac Oncol. 2008 Jul;3(7):735-44. | ||||
| REF 2 | NCBI GEO: archive for functional genomics data sets--update. | ||||
| REF 3 | ClinicalTrials.gov (NCT00590824) Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma. U.S. National Institutes of Health. | ||||
| REF 4 | Clinical pipeline report, company report or official report of Immunservice GmbH. | ||||
| REF 5 | ClinicalTrials.gov (NCT00062036) Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma. U.S. National Institutes of Health. | ||||
| REF 6 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023655) | ||||
| REF 7 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008879) | ||||
| REF 8 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001478) | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.